>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance: COUP -31.8%, CSC -7.9%, AOI -7.8%, SALE -6.3%, SALE -6.3%, ALSN -6.2%, UBS -4%, TAP -3.7%, KS -3.1%, DF -3.1%, IPHI -2.5%, KKR -2.2%, SSNI -1.1%, ACM -0.9%, WPP -0.7%

Select Brazil related names showing weakness: VALE -2.4%, BBD -1.9%, GGB -1.9%, ITUB -1.6%, ABEV -1.4%, SBS -1.4%

Select metals/mining stocks trading lower: RIO -2.2%, AU -1.9%, BHP -1.6%, FCX -1.5%, HMY -1.4%, EGO -1.4%, GFI -0.9%, GG -0.8%, MT -0.7%

Other news: BIOC -35.1% (prices offering of 8 mln shares of common stock and warrants to purchase 8 mln shares at a combined offering price of $1.25), RDHL -17.2% ( announces proposed public offering of its American Depository shares ), REN -10.8% (received continued listing standard notice from NYSE), ANFI -9.5% (cont weakness following yday's cautious Prescience Point report), CAMT -6.9% (Rudolph Tech announced U.S. District Court ruling in Rudolph's patent infringement case against Camtek ), RRMS -5% (announces the commencement of an underwritten public offering of 2 mln common units representing limited partner interests; Rose Rock Midstream to acquire the remaining crude oil assets of SemGroup ), IDRA -2.2% ( announces proposed public offering of common stock to sell up to $75 mln of shares of its common stock ), ATRA -1.6% ( announces that it has commenced an underwritten public offering of 3 mln shares of its common stock), HSBC -1.2% (disclosed placing agreement; transaction will involve the transfer of up to ~952.616 mln ordinary shares of Industrial Bank; will raise a maximum of ~ RMB 12.73 bln), GSK -1.1% (still checking), ADMA -1% ( announced that results from its Phase 2/3 clinical study of ADS-5102 have been published in the online issue of the peer-reviewed journal Movement Disorders)

Analyst comments: RIG -3% (downgraded to Underperform from Neutral at Credit Suisse), FSC -1.1% (downgraded to Equal Weight from Overweight at Barclays), FITB -0.6% (downgraded to Hold from Buy at Deutsche Bank), MAS -0.5% (downgraded to Outperform from Strong Buy at Raymond James
)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance: AMKR +19.7%, ARO +16.3%, (Aeropostale raises guidance, announces two executive appointments), SYN +7.8%, RLD +7%, CMP +6.9%, URBN +6.8%, (reports Q4 revs $1.01 bln vs $998.36 mln Capital IQ Consensus Estimate; Comparable Retail segment net sales, which include comparable direct-to-consumer channel, increased 6%), CGEN+6.3%, QLYS +5.8%, UNIS +5.7%, HOT +5.6%, NSP +5.4%, TDW +5.3%, NEWP +4.8%, FONR +4.7%, KO +4.3%, MPO +3.8%, SFUN +3.5%, GIG +3.4%, NTES +3.3%, SEE +3.3%, WYN +3.1%, QCOM +2.7%, (reaches a resolution with China's National Development and Reform Commission regarding its investigation of Qualcomm under China's Anti-Monopoly Law; co fined $975 mln and raises low end of FY15 guidance), ARWR +2.7%, ALLT +2.7%, CDW +2.6%, AMAG +2.5%, SAVE +2%, CRK +1.5%, IMN +1.2%, NGL +1.1%, MOH +1%

M&A news: KMI +0.9% (to purchase three Vopak U.S. terminals and one undeveloped site for $158 Million)

Select EU financial related names showing strength: NBG +6.2% (volatility surrounding Greece/EU), BBVA +2.1%, IRE +1.3%, SAN +1%, CS +1%

Other news: XGTI +31% (announces $1 mln purchase agreement with Townes Tele-Communications), XON +9.3% (Synthetic Biologics, in collaboration with Intrexon (XON) announces positive topline results from Phase 1b Trial of SYN-004), SYN +7.8% (announces positive topline results from Phase 1b Trial of SYN-004), RLD +7% (announced it has engaged Moelis & Company LLC as its financial advisor to assist in its evaluation of potential strategic alternatives; co also reported earnings), MNOV +2.5% (FDA has approved the protocol for a clinical trial of MN-001 for the treatment of moderate to severe IPF), ACHN +2.5% (cont strength), IBN +2.3% (Sensex strong overnight), TSM +2.1% (reported Jan sales; Board of Directors today adopted a proposal recommending distribution of a NT$4.5 cash dividend per common share), SUNE +2.1% (announces an agreement with PermaCity to develop, build and operate 22 megawatts of rooftop solar as part of the Beacon Bundled Solar contract), TTM +1.7% (sensex strong overnight), MU +1.4% (co and Inotera Memories entered into a supply agreement that amends and restates the existing supply agreement, and a new supply agreement, to take effect as of January 1, 2016), FENG +0.9% (increases strategic investment in Yidian), BABA +0.9% (and Ant Financial announce completion of restructuring)

Analyst comments: CYBR +4.3% (upgraded to Outperform from Market Perform at William Blair), C +1.7% (upgraded to Buy from Hold at Deutsche Bank), BLK +1.7% (target raised to $415 from $405 at BofA/Merrill; Buy -- Added to US 1 List), PTX +1.6% (initiated with a Buy at Cantor Fitzgerald), CRH +1.4% (upgraded to Add at Numis), STJ +1% (upgraded to Buy from Neutral at Sterne Agee), MOS +1% (upgraded to Overweight from Neutral at HSBC Securities), LULU +0.9% (target raised to $70 from $68 at Oppenheimer)

>>> Martin Marietta beats by $0.08, beats on revs; authorized a new share repurc

Martin Marietta beats by $0.08, beats on revs; authorized a new share repurchase program 

Reports Q4 (Dec) earnings of $0.94 per share, $0.08 better than the Capital IQ Consensus Estimate of $0.86; revenues rose 57.1% year/year to $856.3 mln vs the $844.43 mln consensus.
Co authorized a new share repurchase program under which the Company may acquire up to 20 mln shares of its outstanding common stock.
For FY15, co expects:
Aggregates-related downstream product lines to generate between $875 mln and $925 mln of net sales and $65 mln to $70 mln of gross profit.
Net sales for the Cement segment to be between $475 mln and $500 mln, generating $120 mln to $130 mln of gross profit.
Net sales for the Magnesia Specialties segment to be between $240 mln and $250 mln, generating $85 mln to $90 mln of gross profit.

(BFW) Juncker-Tsipras Phone Call Set for This Afternoon, EU Says

--> it looks like mkt is waiting for excuses to trader higher...we would some more news later this afternoon, as sson as they are starting to talk, means there is some willingness to find a solution, we should see mkt continue tio trade higher

BN 02/10 13:08 *EU SPOKESPERSON COMMENTS IN EMAIL ON JUNCKER-TSIPRAS CALL
BN 02/10 13:08 *JUNCKER-TSIPRAS CALL PLANNED AT GREEK REQUEST: EU OFFICIAL
BN 02/10 13:08 *JUNCKER-TSIPRAS PHONE CALL SET FOR THIS AFTERNOON, EU SAYS
Juncker-Tsipras Phone Call Set for This Afternoon, EU Says
2015-02-10 13:11:04.823 GMT


By Rebecca Christie
(Bloomberg) -- EU Commission President Jean-Claude Juncker
is due to speak on the telephone call with Greek Prime Minister
Alexis Tsipras after a request from Greece, EU spokesperson says
in email
* Call will probably take place this afternoon


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Rebecca Christie in Brussels at +32-2-285-4307 or
rchristie4@bloomberg.net
To contact the editors responsible for this story:
Alan Crawford at +49-30-70010-6237 or
acrawford6@bloomberg.net
Rebecca Christie

>>> Omnicom beats by $0.04, beats on revs --> no pre-market

Omnicom beats by $0.04, beats on revs  

Reports Q4 (Dec) earnings of $1.30 per share, $0.04 better than the Capital IQ Consensus Estimate of $1.26; revenues rose 3.4% year/year to $4.2 bln vs the $4.15 bln consensus.
Domestic revenue for the fourth quarter of 2014 increased 8.8% to $2,239.1 million compared to $2,058.6 million in the fourth quarter of 2013. International revenue decreased 2.2% to $1,956.0 million compared to $1,999.5 million in the fourth quarter of 2013.


FT Comment :
Higher ad spending in the US and UK lifted Omnicom revenues and profit in the fourth quarter, capping a strong year for the US advertising holding company despite the collapse of its planned $35bn merger with France's Publicis.

Net income rose 9.7 per cent to $329.5m, or $1.30 a share, from $330.5m, or $1.13 a share, a year ago.

That beat analysts' expectations of $1.26 a share. Revenue increased 3.4 per cent to $4.2bn, compared with estimates of $4.15bn, reports Shannon Bond, US media and marketing correspondent.

Organic revenue grew 5.9 per cent, boosted by 8.5 per cent growth in advertising and a 9.4 per cent lift in its specialty communications business. Organic revenue was up 8.3 per cent in North America and 6.2 per cent in the UK.

Foreign exchange rates weighed, however, dragging organic revenue down 3.1 per cent in the quarter.

For the full year, net income increased 11.4 per cent to $1.1bn, or $4.24 a share, from $991m, or $3.71 a share in 2013, on a 5 per cent gain in revenue to $15.3bn. Organic revenue growth in 2014 of 5.7 per cent was ahead of the 5 per cent the company had targeted.

Omnicom booked $8.8m in pre-tax charges related to the merger with Publicis, which was called off in May after the companies clashed over culture, leadership and tax and regulatory hurdles.

>>> Molson Coors Brewing misses by $0.14, reports beat on revs

Molson Coors Brewing misses by $0.14, reports beat on revs

Reports Q4 (Dec) earnings of $0.55 per share, excluding non-recurring items, $0.14 worse than the Capital IQ Consensus Estimate of $0.69; revenues fell 5.3% year/year to $973.8 mln vs the $966.6 mln consensus.
  • Co announces a new share repurchase program of up to $1.0 bln of Class A and Class B Common stock, with an expected term of four years, which replaces all prior stock repurchase programs. Co anticipates that the stock repurchases will be weighted toward the last two years of the program.
  • Co also raises quarterly dividend by 11% to $0.41 from $0.37 per share. New yield is 2.1%.
  • "Overall, 2014 was a good year for Molson Coors....Weak consumer demand continued across our largest markets, but we made good progress in building a stronger brand portfolio, delivering value-added innovation, strengthening our core brand positions, and increasing our share in above premium."

>>> US Early premarket gappers

Early premarket gappers

Gapping up: ARO +19.7%, AMKR +14.2%, RLD +7%, URBN +7%, RLD +7%, XON +6.9%, CMP +6.9%, HOT +6.7%, QLYS +5.3%, TDW +5.3%, NEWP +4.8%, FONR +4.7%, UNIS +3.7%, GIG +3.4%, TTM +3.1%, SFUN +2.9%, NBG +2.7%, QCOM +2.7%, MCC +2.6%, NTES +2.6%, NOK +2.5%, QCOM +2.4%, YNDX +2.4%, ALLT +2.4%, REGN +2.3%, SAN +2.2%, BBVA +2.1%,PBR +2.1%, CVS +1.9%, C +1.7%, CCL +1.5%, CRK +1.5%, IRE +1.2%, CGEN +1.2%, AMAG +1.1%, NGL +1.1%, CS +1%, BABA +1%, MOH +1%, SAVE +1%

Gapping down: BIOC -33.5%, COUP -28%, CAMT -12.2%, REN -10.8%, SALE -9.6%, SALE -9.6%, CSC -7.9%, ALSN -7.8%, AOI -7.8%, RDHL -7.1%, IDRA -6.4%, SDRL -4.8%, RRMS -4.3%, UBS -3.9%, RIG -3.7%, MRO -3.2%, KS -3.1%, IPHI -2.5%, BHP -2.2%, RIO -2.1%, MT -1.9%, ATRA -1.6%, AU -1.6%, BCS -1.5%, STO -1.5%, HMY -1.4%, EGO -1.4%, GSK -1.2%, GG-1.2%, SSNI -1.1%, ADMA -1%, GFI -0.9%